Biogen Lures Viehbacher Back From Venture Capital As CEO
Executive Summary
Christopher Viehbacher, former Sanofi CEO and current managing partner at Gurnet Capital, will be charged with returning Biogen to growth with a second big Alzheimer’s launch looming.
You may also be interested in...
Biogen’s Latest Leadership Change Hints At Immunology Ambitions
New head of research Jane Grogan comes to Biogen from start-ups Graphite Bio and ArsenalBio, and previously held leadership positions in autoimmune and oncology R&D at Genentech.
Biogen Buys Time For Leqembi Ramp-Up With Reata Acquisition
By agreeing to pay $7.3bn for Reata and its Friedrich’s ataxia drug Skyclarys, “recalibrating” Biogen can be more patient with launches of Alzheimer’s drug Leqembi and ALS therapy Qalsody.
Biogen’s Adam Keeney Focuses On Dealmaking As Growth Strategy Is Made Over
Recently appointed head of corporate development in an ongoing leadership shakeup, Keeney is helping to shape Biogen’s sustainable growth strategy in neuroscience and beyond.